Congress Pearls: Pearls of EADV

Pearls of Congress Overview

In the Congress Pearls on-demand video series, expert faculty present succinct highlights of the latest clinical studies shown at major congresses, with critical insights into how these new data impact daily clinical practice in dermatology and rheumatology. If you have not had the opportunity to attend a major congress, or missed certain important sessions while busy at the congress, catch up by watching these easily accessible,  on-demand short Pearls videos at your own pace.

Episode Overview

In the Pearls of EADV 2022, Prof. Errol Prens, Prof. Lluís Puig, Dr Laura Savage, and Prof. Richard Warren provide their latest updates on current treatments and future outlooks of psoriasis, psoriatic arthritis (PsA), and hidradenitis suppurativa (HS), and discuss the implications these new clinical results will have on patient management and routine practice. These studies were presented at the EADV 2022 Congress in Milan, Italy.

Faculty

Scientific Committee:

Lluís Puig, MD, PhD
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, and Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain

Laura Savage, MD, PhD
Leeds Teaching Hospitals NHS Trust, Faculty of Medicine and Health, University of Leeds, Leeds, UK

Expert speakers:

Errol Prens, MD, PhD
Department of Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands

Richard Warren, MD, PhD
Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, UK

The Pearls of EADV 2022 conversations are divided into five segments:

Part 1: Updates on current psoriasis treatments – Pearls of Dr Savage and Prof. Warren 

With recent advances in the efficacy and safety of biologic therapies for psoriasis, several new studies focus on special populations of interest, such as super responders or patients with comorbidities. Watch this video to learn more about which baseline characteristics predict better response and which associated disorders seem to affect clinical outcomes of psoriasis treatment.

Part 2: What is on the horizon for small molecules? – Pearls of Dr Savage and Prof. Warren

During this congress, we heard many late-breaking presentations about small molecules with promising short- and long-term results even in a paediatric population. Are you curious about the recent data on efficacy and safety of the next generation of oral agents? Please tune in to find out more!           

Part 3: Updates on current psoriatic arthritis treatments – Pearls of Dr Savage and Prof. Warren

As the number of treatment options for PsA has been growing steadily in recent years, the choice of a treatment is more and more dependent on not only the long-term efficacy and safety but also new composite outcome measures. Dr Savage will give you some insight into collaborative working practices between dermatologists and rheumatologists. Tune in to this video to find out how this could impact your clinical practice.      

Part 4: New developments in the management of psoriasis and PsA – Pearls of Prof. Prens and Prof. Puig

In this video, Prof. Prens and Prof. Puig discuss their personal highlights of the management of psoriatic diseases with regard to difficult-to-treat body areas and geographic regions. They also talk about the long-term efficacy and safety of interleukin-23 inhibitors and the improvement of health-related quality of life in patients with moderate to severe psoriasis. Don’t miss this video!

Part 5: New developments in the management of hidradenitis suppurativa – Pearls of Prof. Prens and Prof. Puig

Join us for the last video in the Pearls of EADV 2022 video series, where our expert faculty talk about patient-reported outcomes and the impact of surgery on patients with HS. What new treatment is on the horizon for HS? Watch this video to find out.